


ADITEC is coordinated by the
Sclavo Vaccines Association
Via Fiorentina 1, 53100 Siena Italy,
www.aditecproject.eu



ADITEC: New technologies for improved vaccines

Immunization, the most cost effective health tool ever invented

Immunization is one of the most important health advances in history. Safe and effective, vaccines are a proven tool for controlling and even eliminating devastating infectious disease. Already millions of lives have been saved by vaccinating against deadly diseases like measles, diphtheria, whooping cough, tetanus, polio, mumps, rubella, chicken pox, influenza, meningococcal disease and hepatitis. But we are not there yet.



Today's challenges in vaccine development

The ADITEC (ADvanced Immunization TEChnologies) project was started to develop advanced technologies to solve the issues we still have today.

Because, despite the huge progress already made in the past decades:

- some diseases still do not have a vaccine
- some vaccines currently do not completely protect against disease
- vaccines don't exist for some age groups: new-borns and elderly
- we need vaccines for people with weak immune systems
- and we need new methods of administering the vaccine

New technologies are opening new doors

Progress in science and technology make it possible to achieve what was previously deemed impossible. We now have new tools to develop vaccines and fight previously "untouchable" diseases. However, no single laboratory can do modern vaccine science in isolation. Therefore the ADITEC project was started: to bring all renowned laboratories together to jointly explore new possibilities.

42 Leading institutes collaborate

The ADITEC project was created with €30 million from the European Commission to bring together many of the most competitive European research groups from 12 EU countries, both public institutions and biomedical companies, along with 3 top US groups. This powerful partnership is working to produce the necessary knowledge for developing new and powerful technologies for the next generation of vaccines.

A future with better vaccines for everyone

The highly innovative ADITEC project will lead to new and more effective vaccines. We see a future where vaccines will be administered in novel manners without needles. The formulations will be optimized for different age groups, different genders and for people with chronic diseases. All new insights and technologies will be shared with partners around the world so, in the future, we are better able to combat devastating diseases.

Help us

Immunization saves more than 3 million lives worldwide each year, and it saves millions more from suffering illness and lifelong disability. It is undoubtedly one of the most cost-effective public health achievements of modern times. The benefits of immunization are increasingly being extended across the life course to include adolescents and adults, providing protection against life-threatening diseases such as influenza, meningitis, and cancers that occur in adulthood. Today 1.6 million people still die of HIV, 1.3 of TB, 0.6 of malaria, a few hundred thousand of flu. To decrease these numbers, investments in new technologies are needed. ADITEC is in on the forefront of new innovations with the aim to eradicate all life-threatening diseases in the world.

Dedicated leadership

The ADITEC project is coordinated by the non-profit organization Sclavo Vaccines Association: a dedicated, jointly founded, European not-for-profit NGO, that strives to ensure long-term sustainability of European vaccine R&D efforts.

More information:

www.aditecproject.eu

Facts about ADITEC

Project title: Advanced Immunization Technologies
Duration: Five years (1 Oct 2011 – 30 Sept 2016)
EC contribution: 29.98 million € (~ 20% for SMEs)
Project Coordinator: Rino Rappuoli, Sclavo Vaccines Association
Scientific Coordinator: Donata Medaglini, Sclavo Vaccines Association and University of Siena
Partners: 42 partners from 12 EU countries and the United States
Industrial Involvement: 12 SMEs and 2 big Pharma Industries

ADITEC research partners: 42 partners from 12 EU countries and USA

- Abera Bioscience AB (SE)
- ALTA (IT)
- Bioneedle Group (NL)
- Crossbeta Biosciences (NL)
- DeCODE Genetics (ISL)
- Duoto AB (SE)
- Erasmus Medical Center (NL)
- Emory University Atlanta (USA)
- Fondazione per l'Istituto di Ricerca in Biomedicina (CH)
- Fondazione Humanitas per la Ricerca (IT)
- French Atomic Energy (FR)
- Hookipa Biotech GmbH (AT)
- Infectious Disease Research Institute (USA)
- Institut de Biologie et Chimie des Protéines (CNRS) (FR)
- Institute for Biomedical Aging Research (AT)
- Istituto Superiore di Sanità (IT)
- Institut Pasteur (FR)
- Imperial College London (UK)
- Kings College London (UK)
- Leiden University Medical Center (NL)
- Max-Planck-Institute for Infection Biology (DE)
- Medicine in Need (FR)
- Medicines and Healthcare Products Regulatory Agency (UK)
- Microbiotec s.r.l (IT)
- Novartis Vaccines and Diagnostics (IT)
- Novartis Vaccines Institute for Global Health (IT)
- Okairos (IT)
- Sigmoid Pharma (IE)
- Sclavo Vaccines Association (IT)
- Seattle Biomedical Research Institute (USA)
- Statens Serum Institut (DK)
- Tuberculosis Vaccine Initiative (NL)
- University of Geneva (CH)
- University of Gothenburg (SE)
- University of Oxford (UK)
- University of Siena (IT)
- University of Surrey (UK)
- Utrecht University (NL)
- Vaccibody (NO)
- Valneva Austria GmbH (AT)
- VisMederi s.r.l. (IT)
- World Health Organization (CH)